Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases
- 1 May 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (11) , 5188-5219
Abstract
A highly selective series of inhibitors of the class I phosphatidylinositol 3-kinases (PI3Ks) has been designed and synthesized. Starting from the dual PI3K/mTOR inhibitor 5, a structure-based approach was used to improve potency and selectivity, resulting in the identification of 54 as a potent inhibitor of the class I PI3Ks with excellent selectivity over mTOR, related phosphatidylinositol kinases, and a broad panel of protein kinases. Compound 54 demonstrated a robust PD–PK relationship inhibiting the PI3K/Akt pathway in vivo in a mouse model, and it potently inhibited tumor growth in a U-87 MG xenograft model with an activated PI3K/Akt pathway.Keywords
This publication has 45 references indexed in Scilit:
- PI(3)King Apart PTEN's Role in CancerClinical Cancer Research, 2010
- mTOR and cancer: many loops in one pathwayCurrent Opinion in Cell Biology, 2010
- The PI3K Pathway As Drug Target in Human CancerJournal of Clinical Oncology, 2010
- Novel inhibitors of the PI3K familyExpert Opinion on Investigational Drugs, 2009
- Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProceedings of the National Academy of Sciences, 2008
- Cancer-specific mutations in phosphatidylinositol 3-kinaseTrends in Biochemical Sciences, 2007
- The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer TherapyClinical Cancer Research, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- PHOSPHOINOSITIDE KINASESAnnual Review of Biochemistry, 1998